Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington’s Disease Patients

The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of... Background:Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder that typically manifests between the ages of 30 and 50 years. However, the disease can present at any age, and phenotypic differences between younger and later-onset patients have received limited attention.Objective:To compare clinical features of late- (>70 years of age) and younger-onset (<30 years of age) HD patients.Methods:Patients presenting to our regional NHS HD clinic with new-onset manifest HD diagnosed over the age of 70 years (LoHD) (n = 18) were compared with a younger cohort who developed disease under the age of 30 years (YoHD) (n = 12). Rate of progression over time on standard cognitive and motor measures was compared.Results:At first clinic presentation, both groups had the same total UHDRS scores. However, the LoHD group had higher chorea scores (F (1,28) = 6.52, p = 0.016), while the YoHD group had more dystonia (F (1,28) = 8.69, p = 0.006) and eye movement abnormalities (F (1,28) = 16.991, p < 0.001). The YoHD group also had a greater rate of motor progression, especially for bulbar measures (F (1, 28) = 6.96, p = 0.013) and bradykinesia (F (1, 28) = 7.99, p = 0.009). No differences were found in the rate of cognitive change (F (1,21) = 1.727, p = 0.203) nor functional capacity (F (1,28) = 1.388, p = 0.249) between the groups.Conclusion:Phenotypic differences between YoHD and LoHD patients were found in terms of initial presentation and rate of motor progression. This has implications for therapeutic trials involving HD patients of different ages, given their different clinical features and progression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Huntington's Disease IOS Press

The Clinical Features and Progression of Late-Onset Versus Younger-Onset in an Adult Cohort of Huntington’s Disease Patients

Download PDF
8 pages

Loading next page...
 
/lp/ios-press/the-clinical-features-and-progression-of-late-onset-versus-younger-HUHuMTXR7t

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2020 © 2020 – IOS Press and the authors. All rights reserved
ISSN
1879-6397
eISSN
1879-6400
DOI
10.3233/JHD-200404
Publisher site
See Article on Publisher Site

Abstract

Background:Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder that typically manifests between the ages of 30 and 50 years. However, the disease can present at any age, and phenotypic differences between younger and later-onset patients have received limited attention.Objective:To compare clinical features of late- (>70 years of age) and younger-onset (<30 years of age) HD patients.Methods:Patients presenting to our regional NHS HD clinic with new-onset manifest HD diagnosed over the age of 70 years (LoHD) (n = 18) were compared with a younger cohort who developed disease under the age of 30 years (YoHD) (n = 12). Rate of progression over time on standard cognitive and motor measures was compared.Results:At first clinic presentation, both groups had the same total UHDRS scores. However, the LoHD group had higher chorea scores (F (1,28) = 6.52, p = 0.016), while the YoHD group had more dystonia (F (1,28) = 8.69, p = 0.006) and eye movement abnormalities (F (1,28) = 16.991, p < 0.001). The YoHD group also had a greater rate of motor progression, especially for bulbar measures (F (1, 28) = 6.96, p = 0.013) and bradykinesia (F (1, 28) = 7.99, p = 0.009). No differences were found in the rate of cognitive change (F (1,21) = 1.727, p = 0.203) nor functional capacity (F (1,28) = 1.388, p = 0.249) between the groups.Conclusion:Phenotypic differences between YoHD and LoHD patients were found in terms of initial presentation and rate of motor progression. This has implications for therapeutic trials involving HD patients of different ages, given their different clinical features and progression.

Journal

Journal of Huntington's Disease – IOS Press

Published: Oct 8, 2020

References

  • The Huntington’s Disease Collaborative Research Group
    A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes
  • Huntington’s disease: A clinical review
    Roos
  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
    Lee
  • A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
    Ciosi
  • What do we know about late onset Huntington’s disease?
    Chaganti
  • Late-onset Huntington’s disease: A clinical and molecular study
    James
  • Huntington’s disease with onset ages greater than 60 years
    Yoshida
  • Late onset Huntington disease: Clinical and genetic characteristics of 34 cases
    Lipe
  • Late-onset Huntington’s disease: Diagnostic and prognostic considerations
    Koutsis
  • Clinical and molecular features of late onset Huntington disease in a Peruvian cohort
    Cornejo-Olivas
  • Hereditary late-onset chorea without significant dementia: Genetic evidence for substantial phenotypic variation in Huntington’s disease
    Britton
  • Cognitive impairment in Huntington disease: Diagnosis and treatment
    Paulsen